If this proves correct, blood-brain barrier penetrance may be the wrong language for a real but poorly understood phenomenon, and compound design should target whatever route actually delivers these peptides to the relevant neurons
Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models
1,2 For this reason, its important to further understand the mechanism of GLP-1 therapies, said Lorenzo Leggio, a neuroendocrinologist at the National Institute on Drug Abuse who mediated the GLP-1 press conference at the 2025 Society for Neuroscience meeting
Editor's Note: The NNTs and NNHs were calculated by the authors based on data in the systematic review
July 2024, Roche announced that its oral GLP-1 receptor agonist GLP-1 Agonists Target Patient Pool Analysis: between 2014 and 2018, only In a study by Watanabe et al